Quantitative Proteomics: A Major Piece in the Precision Medicine Puzzle

Posted on December 22nd, 2017 by Betsy Davis in Pharma R&D

Our genetic make-up, where we live and how we live, are all important factors to consider when we are dealing with disease. For a very long time, medicine has mostly been designed to treat the sickness without much thought to the individual who has it. But precision medicine is a newer tactic that is utilizing advances and technologies that help us obtain more data about ourselves to consider diseases in a more personalized way.

Genome sequencing was especially key to driving this more precise approach, but there is still so much more to learn. Genomics is only “one piece of the puzzle,” as science writer Karen Steward puts it. “Genetics cannot predict the diversity of protein expression patterns, modifications or how proteins may interact following translation. Therefore,” she asserts, “studying the proteome of individuals and incorporating this information with genetic data has been key in advancing the field.”

She identifies mass spectrometry-based quantitative proteomics as an especially important tool in the further growth of precision medicine. Find out why, and also learn about challenges in proteomics in her article Quantitative Proteomics in Precision Medicine, published in Technology Networks.

---

All opinions shared in this post are the author’s own.

R&D Solutions for Pharma & Life Sciences

We're happy to discuss your needs and show you how Elsevier's Solution can help.

Contact Sales

Betsy Davis
Senior Strategic Marketing Manager

Connect on LinkedIn
Follow on Twitter
https://elsevier.com

Related posts

• Dr. Anton Yuryev discusses pathways and precision medicine at PMWC
• What’s ahead for the Life Sciences industry?
• ‘Tis the season to have your own pharma-themed film festival
• The Hive is now open for 2020 applications
• The Beneficial Impacts of Real-World Evidence in Drug Development